Dr. Paulmurugan has expertise in molecular imaging, pre-clinical cancer imaging, cancer biology, nanotechnology, and molecular biotechnology. Dr. Massoud has expertise in molecular imaging, translational cancer imaging, neuro-oncology, and applications and perspectives relevant to clinical cancer management of glioblastoma patients.

Select Guide Rating

• 1. Overview of glioblastoma biological hallmarks and molecular pathology2. Past and present drug treatments for glioblastoma3. Investigational new drugs against glioblastoma4. Molecular mechanimsms in temozolomide-resistant glioblastoma5. Glioma stem cells and associated molecular mechanisms in Glioblastoma6. Signaling in the tumor microenvironment of therapy-resistant glioblastoma7. Intratumoral heterogeneity associated with glioblastoma drug response and resistance8. Role of apoptosis, autophagy, and the unfolded protein response in glioblastoma chemoresistance9. Role of multidrug resistance in glioblastoma chemoresistance: Focus on ABC transporters10. Role of mitochondrial reactive oxygen species in glioblastoma drug resistance and strategies for therapeutic interventions11. Glioblastoma cell-induced immunosuppression causing chemoresistance12. Role of cell quiescence in glioblastoma cytotoxic resistance and strategies for therapeutic intervention13. The molecular and cellular effects of radiotherapy-induced microenvironment changes on potential chemoresistance in glioblastoma14. Molecular and cellular mechanism in recurrent glioblastoma chemoresistance15. Role of long noncoding RNAs in temozolomide-resistant glioblastoma16. Mechanisms of glioblastoma resistance to antiangiogenic agents and reversal approaches17. Treatment and resistance of glioblastoma to CAR T-cell immunotherapies18. On chip analysis of glioblastoma cell chemoresistance19. Three-dimensional in vitro models to study potentiation of glioblastoma resistance by hypoxia20. Chemoresistance mechanisms in mouse models of glioblastoma21. Therapeutic approaches to overcome temozolomide resistance in glioblastoma22. Understanding signal transduction pathways to overcome targeted therapy resistance in glioblastoma23. Targeting the molecular mechanisms of glioma stem cell resistance to chemotherapy24. Immunotherapy for glioblastoma as a means to overcome resistance to standard therapy25. Role of microRNA therapy in presensitizing glioblastoma cells to temozolomide treatment26. Drug penetration through the blood-brain barrier after radiotherapy: New approaches to bypass glioblastoma chemoresistance27. Nanoparticles beyond the blood-brain barrier for glioblastoma28. Small molecules targeting misfolded mutants of p53 as a rescue strategy to improve glioblastoma chemotherapy29. p53 supplementation as a targeted cancer gene therapy for glioblastoma

Dr. Paulmurugan has expertise in molecular imaging, pre-clinical cancer imaging, cancer biology, nanotechnology, and molecular biotechnology. Dr. Massoud has expertise in molecular imaging, translational cancer imaging, neuro-oncology, and applications and perspectives relevant to clinical cancer management of glioblastoma patients.

Select Guide Rating

• 1. Overview of glioblastoma biological hallmarks and molecular pathology2. Past and present drug treatments for glioblastoma3. Investigational new drugs against glioblastoma4. Molecular mechanimsms in temozolomide-resistant glioblastoma5. Glioma stem cells and associated molecular mechanisms in Glioblastoma6. Signaling in the tumor microenvironment of therapy-resistant glioblastoma7. Intratumoral heterogeneity associated with glioblastoma drug response and resistance8. Role of apoptosis, autophagy, and the unfolded protein response in glioblastoma chemoresistance9. Role of multidrug resistance in glioblastoma chemoresistance: Focus on ABC transporters10. Role of mitochondrial reactive oxygen species in glioblastoma drug resistance and strategies for therapeutic interventions11. Glioblastoma cell-induced immunosuppression causing chemoresistance12. Role of cell quiescence in glioblastoma cytotoxic resistance and strategies for therapeutic intervention13. The molecular and cellular effects of radiotherapy-induced microenvironment changes on potential chemoresistance in glioblastoma14. Molecular and cellular mechanism in recurrent glioblastoma chemoresistance15. Role of long noncoding RNAs in temozolomide-resistant glioblastoma16. Mechanisms of glioblastoma resistance to antiangiogenic agents and reversal approaches17. Treatment and resistance of glioblastoma to CAR T-cell immunotherapies18. On chip analysis of glioblastoma cell chemoresistance19. Three-dimensional in vitro models to study potentiation of glioblastoma resistance by hypoxia20. Chemoresistance mechanisms in mouse models of glioblastoma21. Therapeutic approaches to overcome temozolomide resistance in glioblastoma22. Understanding signal transduction pathways to overcome targeted therapy resistance in glioblastoma23. Targeting the molecular mechanisms of glioma stem cell resistance to chemotherapy24. Immunotherapy for glioblastoma as a means to overcome resistance to standard therapy25. Role of microRNA therapy in presensitizing glioblastoma cells to temozolomide treatment26. Drug penetration through the blood-brain barrier after radiotherapy: New approaches to bypass glioblastoma chemoresistance27. Nanoparticles beyond the blood-brain barrier for glioblastoma28. Small molecules targeting misfolded mutants of p53 as a rescue strategy to improve glioblastoma chemotherapy29. p53 supplementation as a targeted cancer gene therapy for glioblastoma

Dr. Paulmurugan has expertise in molecular imaging, pre-clinical cancer imaging, cancer biology, nanotechnology, and molecular biotechnology. Dr. Massoud has expertise in molecular imaging, translational cancer imaging, neuro-oncology, and applications and perspectives relevant to clinical cancer management of glioblastoma patients.

Select Guide Rating

• 1. Overview of glioblastoma biological hallmarks and molecular pathology2. Past and present drug treatments for glioblastoma3. Investigational new drugs against glioblastoma4. Molecular mechanimsms in temozolomide-resistant glioblastoma5. Glioma stem cells and associated molecular mechanisms in Glioblastoma6. Signaling in the tumor microenvironment of therapy-resistant glioblastoma7. Intratumoral heterogeneity associated with glioblastoma drug response and resistance8. Role of apoptosis, autophagy, and the unfolded protein response in glioblastoma chemoresistance9. Role of multidrug resistance in glioblastoma chemoresistance: Focus on ABC transporters10. Role of mitochondrial reactive oxygen species in glioblastoma drug resistance and strategies for therapeutic interventions11. Glioblastoma cell-induced immunosuppression causing chemoresistance12. Role of cell quiescence in glioblastoma cytotoxic resistance and strategies for therapeutic intervention13. The molecular and cellular effects of radiotherapy-induced microenvironment changes on potential chemoresistance in glioblastoma14. Molecular and cellular mechanism in recurrent glioblastoma chemoresistance15. Role of long noncoding RNAs in temozolomide-resistant glioblastoma16. Mechanisms of glioblastoma resistance to antiangiogenic agents and reversal approaches17. Treatment and resistance of glioblastoma to CAR T-cell immunotherapies18. On chip analysis of glioblastoma cell chemoresistance19. Three-dimensional in vitro models to study potentiation of glioblastoma resistance by hypoxia20. Chemoresistance mechanisms in mouse models of glioblastoma21. Therapeutic approaches to overcome temozolomide resistance in glioblastoma22. Understanding signal transduction pathways to overcome targeted therapy resistance in glioblastoma23. Targeting the molecular mechanisms of glioma stem cell resistance to chemotherapy24. Immunotherapy for glioblastoma as a means to overcome resistance to standard therapy25. Role of microRNA therapy in presensitizing glioblastoma cells to temozolomide treatment26. Drug penetration through the blood-brain barrier after radiotherapy: New approaches to bypass glioblastoma chemoresistance27. Nanoparticles beyond the blood-brain barrier for glioblastoma28. Small molecules targeting misfolded mutants of p53 as a rescue strategy to improve glioblastoma chemotherapy29. p53 supplementation as a targeted cancer gene therapy for glioblastoma